This educational program is intended for urologists, oncologists, nurse practitioners, and other healthcare professionals who care for patients with prostate cancer. This educational program is also intended to reach patients with prostate cancer and their caregivers.
The goal of this activity is to educate urologists, oncologists, nurse practitioners, nurses, pharmacists, other healthcare professionals, and patients and caregivers about recent developments in the treatment of prostate cancer to optimally individualize equitable care for every patient.
Upon completion of this activity, participants should be able to:
Integrate new and emerging data for the treatment of advanced or metastatic prostate cancer into current clinical practice to optimize clinical outcomes
Plan individualized therapeutic strategies for metastatic prostate cancer, considering all available agents, optimal agent sequence, available clinical data, expert recommendations, and patient goals and preferences
Counsel patients with metastatic prostate cancer and their caregivers on available treatment options, considering differences in administration, safety profiles, efficacy, and individual patient comorbidities and goals
Evaluate strategies to promote health equity in the care of patients with prostate cancer, including access to care, treatment, and clinical outcomes
Refer appropriate patients with prostate cancer to ongoing clinical trials investigating novel therapies throughout the disease continuum
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Alicia Morgans, MD, MPH
Associate ProfessorDana-Farber Cancer Institute Boston, Massachusetts
Alicia K. Morgans, MD, MPH: consultant/advisor/speaker: AAA, Astellas, AstraZeneca, Bayer, Dendreon, Foundation Medicine, Exelixis, Janssen, Lantheus, Myovant, Myriad, Novartis, Pfizer, Sanofi, SeaGen, Telix.
Tanya B. Dorff, MD
Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Tanya B. Dorff, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Janssen, Sanofi.
Rana R. McKay, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California
Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Lilly, Myovant, Merck, Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus.
Michael Schweizer, MD
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Michael T. Schweizer, MD: consultant/advisor/speaker: AstraZeneca, PharmaIn, Sanofi; researcher (paid to institution): Ambrx, AstraZeneca, Bristol Myers Squibb, Epigenetics, Epigenetix, Hoffman-La Roche, Immunomedics, Incyte, Janssen, Merck, Novartis, Pfizer, SignalOne Bio, Tmunity, Xencoer, Zenith.
David VanderWeele, MD, PhD
Department of Hematology/Oncology
Department of Hematology/Oncology
Jesse Brown VA Medical Center
David VanderWeele, MD, PhD: consultant/advisor/speaker: Astellas, AstraZeneca Bayer, Exelixis, Janssen, Myovant; researcher (paid to institution): AstraZeneca, Bayer, Genentech.
The planners and content peer reviewers from Clinical Care Options, LLC and ZERO Prostate Cancer do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from August 16, 2023, through August 15, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
The program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-204-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.